Early Prescribing Patterns for TV-46000 Since US FDA Approval for the Treatment of Schizophrenia in Adults: A US Claims Database Analysis
Background: TV-46000, a subcutaneous long-acting injectable risperidone formulation administered once monthly (q1m) or once every 2 months (q2m), was approved in the US in April 2023 for adults with schizophrenia. This analysis examines prescribing patterns for TV-46000, focusing on lines of therapy (LOT).
Methods: EVERSANA US administrative claims data from July 2018–February 2024 were examined. Adults prescribed TV-46000 with ≥2 months of data prior to index date, or activity before May 1, 2023, were included. Index date was first TV-46000 claim date or first schizophrenia diagnosis date. LOT analysis included patients with ≥1 year of history prior to first claim for schizophrenia diagnosis.
Results: Of 715 adults with schizophrenia prescribed TV-46000, most received TV-46000 q1m (79%, 563/715) versus q2m (21%, 152/715); 69% (66% for q1m and 81% for q2m) were adherent, defined as proportion of days covered ≥80%.
LOT analysis found that 311 patients were switched to TV-46000 from other treatments, most commonly oral second-generation antipsychotics (SGAs) (32%, 98/311), among which risperidone was most common (45%, 44/98). Overall, 17% (64/378) of patients were switched from TV-46000 to another treatment, most commonly oral SGAs (45%, 29/64), among which risperidone was most common (41%, 12/29); 83% (314/378) of patients were not switched. For LOT, the most common first-line treatments in this population were oral SGAs (42%, 158/378) and TV-46000 (12%, 46/378).
Conclusions: Adherence with TV-46000 was high, particularly with q2m dosing. During the 10 months since TV-46000 approval, patients prescribed TV-46000 had most commonly received oral SGAs as first-line schizophrenia treatment.
